Status:
UNKNOWN
Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents (DAA) on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
HIV Associated HCV
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Spontaneous recovery of patients infected with HCV is related to the development of a cytotoxic immune response that is executed by specialized white blood cells, the CD8+ T cells, which develop a vir...
Eligibility Criteria
Inclusion
- HIV1 infected patient
- HCV positive serologie and RNA-HCV positive
- Starting an anti-HCV traitment with direct antiviral agent
- With an hepatic fibrosis score \< 12,5KPa measured through elastometry or with a score \< F4 from liver biopsy
Exclusion
- HIV2 infected patients par le VIH2
- Positive for HBsAg,
- Cirrohtic patient (elastométry \>12,5kPa or métavir score F4)
Key Trial Info
Start Date :
August 31 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2019
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03244371
Start Date
August 31 2016
End Date
February 28 2019
Last Update
August 9 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique Hôpitaux de Marseille
Marseille, France, 13273